

1 **Estimating the potential need and impact of SARS-CoV-2 test-and-treat programs with**
2 **oral antivirals in low-and-middle-income countries**

3

4 Alvin X. Han^{1,*}, Emma Hannay², Sergio Carmona², Bill Rodriguez², Brooke E. Nichols^{1,2,3,†},
5 Colin A. Russell^{1,3,†,*}

6

7 ¹Department of Medical Microbiology & Infection Prevention, Amsterdam University
8 Medical Center, University of Amsterdam, Amsterdam, The Netherlands

9

²Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland

10 ³Department of Global Health, School of Public Health, Boston University, Boston, MA,
11 USA

12

13 †Contributed equally

14 *Correspondence to Alvin X. Han (x.han@amsterdamumc.nl) and Colin A. Russell
15 (c.a.russell@amsterdamumc.nl)

16

17 **Abstract (149/150 words)**

18 Oral antivirals can potentially reduce the burden of COVID-19. However, low SARS-CoV-2
19 clinical testing rates in many low- and middle-income countries (LMICs) (mean <10
20 tests/100,000 people/day, July 2022) makes the development of effective test-and-treat
21 programs challenging. Here, we used an agent-based model to investigate how testing rates
22 and strategies could affect development of test-and-treat programs in three representative
23 LMICs. We find that at <10 tests/100,000 people/day, test-and-treat programs are unlikely to
24 have any impact on the public health burden of COVID-19. At low effective transmission
25 rates ($R_t \leq 1.2$), increasing to 100 tests/100,000 people/day and allowing uncapped
26 distribution of antivirals to LMICs (estimate = 26,000,000-90,000,000 courses/year for all
27 LMICs), could avert up to 65% of severe cases, particularly in countries with older
28 populations. For higher R_t , significant reductions in severe cases are only possible by
29 substantially increasing testing rates or restricting clinical testing to those with higher risk of
30 severe disease.

31

32 **Main text (3,466/3,500 words excluding Online Methods)**

33 **Introduction**

34 Antiviral therapies such as anti-SARS-CoV-2 monoclonal antibodies, replication inhibitors,
35 protease inhibitors, and host-directed therapies can be used to treat COVID-19, reducing the
36 probability of severe disease to varying degrees.¹ Direct-acting antiviral drugs, such as
37 molnupiravir² and nirmatrelvir–ritonavir (Paxlovid),³ have the potential to substantially lower
38 disease burden given their efficacy and convenience of oral dosing. Nirmatrelvir–ritonavir, in
39 particular, can reduce incidence of adverse events in high-risk individuals (i.e. ≥ 60 years of
40 age (over-60y) or an adult ≥ 18 years with a relevant comorbidity) by 46-89%.^{3,4} Given their
41 ability to lower viral load,³ these drugs could also potentially be used to control SARS-CoV-2
42 transmission.⁵ To achieve maximum impact, these drugs must typically be administered
43 within a few days of symptom onset. Given the current limited availability and relatively high
44 cost of these drugs,⁶ along with the need to administer drugs quickly after symptom onset,^{2,3}
45 diagnostic testing remains an essential first step for identifying suitable drug recipients.

46

47 Just like in high-income countries, oral antivirals (the term “*antivirals*” refers only to oral
48 direct antivirals for the rest of this article) have the potential to reduce the disease burden of
49 COVID-19 outbreaks in low- and middle-income countries (LMICs). However, there have
50 been substantial gaps in COVID-19 testing equity across country income groups throughout
51 the pandemic. Between January 2020 and March 2022, LMICs were only testing at an
52 average of 27 tests/100,000 people/day (tests/100K/day) as compared to >800 tests/100K/day
53 in high-income countries (HICs).⁷ In the post-crisis phase of the pandemic, testing rates
54 dwindled down to just 10 tests/100K/day and 500 tests/100K/day on average for LMICs and
55 HICs respectively (as of June 2022).⁷ Persistently low testing rates severely underestimate
56 COVID-19 cases in LMICs,⁸ which not only complicate antiviral demand forecasts but create
57 additional barriers to the effective use of antivirals if and when they become widely available
58 in LMICs.

59

60 Here, we used the Propelling Action for Testing And Treating (PATAT) agent-based
61 model^{9,10} to demonstrate how testing rates and testing strategies affect the use and impact of
62 antivirals, particularly in LMICs. In the model, we focused on antigen rapid diagnostic tests
63 (Ag-RDTs) which can easily be performed at point of care or be used as self-tests with short
64 turnaround time needed to quickly identify high-risk infected individuals.¹¹ We computed the

65 potential impact of test-and-treat programs on infections, severe cases, and deaths averted in
66 three LMICs with distinct demographic structures – Brazil, Georgia, and Zambia – as well as
67 the Netherlands as a HIC example, all under varying levels of vaccination coverage. Our
68 findings highlight the limits and expected outcomes of COVID-19 oral antiviral treatment
69 programs under realistic testing and vaccination landscapes.

70

71 **Results**

72 *Impact of oral antivirals in low- and middle-income countries*

73 We first simulated Omicron BA.1-like epidemic waves in three different LMICs (Brazil,
74 Georgia, and Zambia) with distinct population demographics (i.e. age distribution and contact
75 networks; Extended Data Fig. 1) under different levels of vaccine coverage, epidemic
76 intensity (R_t), and test availability. We assumed that only symptomatic individuals seek
77 clinical testing, and that only test-positive, high-risk (i.e. ≥ 60 years of age (over-60y) or an
78 adult ≥ 18 years with a relevant comorbidity) individuals receive a course of antivirals.

79

80 At the mean LMIC testing rate of 10 tests/100K/day, test-and-treat programs are unlikely to
81 have any population-level impact on disease transmission in any setting (Extended Data Fig.
82 2). At higher testing rates (≥ 100 tests/100K/day) and lower R_t (≤ 1.5) there were modest
83 differences between simulated countries. We found that current antivirals have only limited
84 impact on total infections averted (Extended Data Fig. 2), in large part because 58-67% of all
85 transmission events are attributed to asymptomatic and pre-symptomatic individuals
86 (Extended Data Fig. 3A). In Georgia, where $>30\%$ of the population are over-60y and high-
87 risk individuals transmitted almost half of all infections (Extended Data Fig. 3B), increasing
88 testing rates to 100 (500) tests/100K/day, accompanied by uncapped distribution of antivirals,
89 could reduce total infections by 12% (22%). On the other hand, regardless of testing rates,
90 infections averted diminished to $<12\%$ and $<4\%$ in Brazil and Zambia respectively, both of
91 which have small over-60y populations (i.e. Brazil: 15%; Zambia: 6% of population;
92 Extended Data Fig. 3A) and where most infections are transmitted by low-risk individuals
93 (Extended Data Fig. 3B). Across all settings and testing rates, increasing vaccination
94 coverage did not change the impact of antiviral distribution on infections averted
95 substantially.

96

97 If testing rates could be increased to 500 tests/100K/day, the proportion of severe cases
98 averted due to antivirals depends on the proportion of over-60y in the population, with
99 Georgia, Brazil, and Zambia maximally reducing up to an average of 67%, 55%, and 46% of
100 severe cases respectively through test-and-treat strategies (Fig. 1). Linking antiviral treatment
101 to testing programs at a rate of 10 tests/100K/day does not generate any impact under any
102 scenario, including when 90% of the population are vaccinated. Raising testing rates to 100
103 tests/100K/day – a widely publicized global target – and treating all high-risk, test-positive
104 patients with antivirals substantially increased the proportion of severe cases averted at lower
105 R_t (i.e. proportion of severe cases averted at $R_t = 0.9$ (1.2) with 10-90% vaccination
106 coverage: Brazil, 24-55% (6-14%); Zambia, 17-20% (3-4%); and Georgia 50-65% (13-30%)
107 (Fig. 1); the impact was greatest in Georgia given its substantial >60y population. As R_t
108 increases (≥ 1.5), the likely population demand for tests also increases, and correspondingly
109 >100 tests/100K/day is needed to ensure that high-risk individuals can be identified to initiate
110 treatment (i.e. proportion of severe cases averted at $R_t = 1.5$ (2.0) with 10-90% vaccination
111 coverage at 100 tests/100K/day: Brazil, 1-4% (0-1%) ; Zambia, 2-4% (0-3%) ; Georgia, 3-9%
112 (1-2%); At 500 tests/100K/day: Brazil, 11-36% (6-9%); Zambia, 9-16% (7-9%); Georgia, 24-
113 66% (8-14%); Fig. 1).

114
115 While no degree of vaccination coverage enables an effective antiviral treatment program at
116 low testing rates, when testing levels are adequate, increasing vaccination coverage will
117 augment the benefit of antivirals in reducing severe cases (Table 1). The greatest benefit
118 increase of antivirals through wider vaccination coverage is at levels of R_t where testing rates
119 would have otherwise been insufficient to satisfy symptomatic testing demand at lower
120 vaccine coverage. For instance, at $R_t = 1.5$ and 100 tests/100K/day, there is a 3.0-fold
121 increase in the proportion of severe cases averted by boosting vaccination coverage from
122 10% to 90% in Brazil, and a 2.0-fold increase in Zambia; in Georgia with its larger over-60y
123 population, boosting vaccination coverage to 90% results in a 3.4-fold increase in severe
124 cases averted. Although we did not model the impact of antivirals in reducing the likelihood
125 of death, developing severe disease precedes dying from COVID-19 in our model (see
126 Methods), the number of deaths averted thus follow similar trends as severe cases averted
127 (Extended Data Fig. 4).

128

129 *Distribution of oral antivirals to high-risk household contacts*

130 As antivirals must be administered quickly after symptom onset, one way to promptly
131 identify and treat infected high-risk individuals is to secondarily distribute self-tests to high-
132 risk household contacts who were exposed to the test-positive individuals. We repeated our
133 simulations with high-risk household contacts receiving Ag-RDTs to self-test over the
134 ensuing three days, initiating antiviral treatment upon a positive diagnosis. In this scenario,
135 however, there is little reduction in total infections due to antivirals (Extended Data Fig. 5).
136 In fact, when R_t is low (≤ 1.2) and at 100 tests/100K/day, self-testing high-risk household
137 contacts diverted test stocks away from test-seeking symptomatic individuals that would
138 otherwise might have been diagnosed and changed their behavior to lower transmissions. In
139 other words, secondary self-testing and treatment approach resulted in more infections than if
140 antivirals were not distributed at all.

141

142 At 100 tests/100K/day across all R_t values, or at 500 tests/100K/day and higher R_t , the
143 proportion of severe cases and in turn, deaths averted diminished substantially by a factor of
144 two- to ten-fold relative to no secondary distribution of Ag-RDTs (Extended Data Figs. 6-7).
145 Even when there were ample tests for both symptomatic individuals and high-risk household
146 contacts (i.e. 500 tests/100K/day and $R_t = 0.9$), there was no substantial reduction in severe
147 cases and deaths. Crucially, 100 tests/100K/day remains inadequate to meet the testing
148 demand of symptomatic individuals and high-risk household contacts that the beneficial
149 effects on severe case reduction under higher vaccination coverage was only observed at 500
150 tests/100K/day (i.e. at $R_t = 1.5$ with 500 tests/100K/day, fold increase in proportion of
151 severe cases averted by boosting vaccination coverage from 10% to 90%: Brazil, 3.2-fold;
152 Zambia, 2.2-fold; Georgia, 4.3-fold).

153

154 *Restricting symptomatic testing to high-risk individuals*

155 Given the limited impact of current antivirals in reducing transmissions, testing could be
156 targeted to high-risk individuals only in order to distribute antivirals to as many infected
157 high-risk individuals as possible. This strategy can be effective when Ag-RDT availability is
158 inadequate to test all symptomatic individuals who seek testing, which has been a common
159 scenario in LMICs throughout the pandemic. Otherwise, if most individuals only isolate
160 themselves after a positive test, the testing restriction would lead to excess tests available that
161 are not effectively used to alter the behaviour of low-risk infected individuals that curb
162 onward transmissions.

163

164 In our model, restricting testing to high-risk groups when there are sufficient amounts of test
165 to diagnose all symptomatic individuals resulted in more transmissions (up to 56% more
166 infections particularly when $R_t \leq 1.5$, 500 tests/100K/day and/or higher vaccination
167 coverage; Extended Data Fig. 8) and a higher number of severe cases (Fig. 2; e.g. 52% (66%)
168 reduction in severe cases in Georgia at $R_t = 1.5$, 500 tests/100K/day and 90% vaccination
169 coverage with (without; Fig. 1) symptomatic testing restrictions). On the other hand, when
170 operating under limited test availability relative to R_t , restricting symptomatic testing to
171 maximally test-and-treat high-risk individuals could be an effective strategy to further reduce
172 severe cases (i.e. Fold increase in proportion of severe cases averted than no symptomatic
173 testing restrictions when $R_t \geq 1.5$, across all vaccination coverage and LMICs simulated: 100
174 tests/100K/day, median 4.9-fold (interquartile range (IQR) = 3.3-6.4); 500 tests/100K/day,
175 median 3.2-fold (IQR = 2.4-5.1)) and in turn, deaths as well (Extended Data Fig. 9).

176

177 *Impact of oral antivirals in high-income countries*

178 We also simulated Omicron BA.1-like epidemic in the Netherlands as a HIC archetype. We
179 assumed that 80% of the population have been fully vaccinated and that over-the-counter Ag-
180 RDTs for self-testing are widely available, such that only a small proportion (10%) of
181 symptomatic individuals seek clinic-provided testing directly. Most individuals who did not
182 seek clinic-provided testing (80%) would instead perform a self-test using over-the-counter
183 Ag-RDTs. All high-risk individuals who tested positive using self-tests would then seek
184 reflexive testing at clinics on the same day to be administered antivirals (see Methods).

185

186 Under these assumptions, we found that in combination with the current mean HIC clinic-
187 provided testing rate of 500 tests/100K/day, distribution of antivirals could avert 56-59% of
188 severe cases and 67-70% of deaths on average, regardless of the epidemic intensity (Fig. 3).
189 Given that the age distribution of the Netherlands is broadly similar to that of Georgia, there
190 was a modest reduction in total infections due to antivirals, but it did not amount to more than
191 an average of 13%. However, if mean clinic-provided testing rates were to fall to 100
192 tests/100K/day, the mean proportion of severe cases and deaths averted would also drop
193 precipitously to as low as 14% and 19% respectively when $R_t \geq 1.5$. Since antivirals must be
194 administered promptly upon a positive diagnosis, we also computed the proportion of high-
195 risk, symptomatic individuals that would miss the treatment window if they had sought

196 reflexive testing late. Regardless of clinical testing rate and R_t , for $\geq 90\%$ of high-risk
197 symptomatic individuals who were able to avert severe disease outcomes through the
198 antiviral to be treated with the drug, they must not seek reflexive testing at clinics (if
199 reflexive testing is required) later than two days after being tested positive with over-the-
200 counter self-tests (Extended Data Fig. 11).

201

202 *Oral antiviral need*

203 By assuming that all test-positive, high-risk individuals received an antiviral course, we
204 estimated the amount of antiviral needed in each simulated scenario (Fig. 4). We assumed
205 that vaccine protection against infection was low (30%) and that antivirals were distributed
206 regardless of vaccination status. As such, increasing vaccination coverage did not lower
207 antiviral need substantially (median 0.93-fold change (IQR = 0.70-1.00) when vaccination
208 coverage increased from 10% to 90%). Conversely, the amount of antivirals distributed
209 depends on R_t (median 2.60-fold change (IQR = 0.97-4.35) when R_t increases from 0.9 to
210 2.0), country demographics (median 1.72-fold change (IQR=1.02-2.04) when distributing
211 antivirals in Georgia relative to Zambia), testing rates (median 4.31-fold change (IQR = 1.49-
212 5.77) when increasing from 100 to 500 tests/100K/day), and how tests were targeted (median
213 2.57-fold change (IQR = 1.52-4.55) when testing only high-risk as opposed to all
214 symptomatic individuals).

215

216 In the Netherlands, even though only 10% of symptomatic individuals sought clinic-provided
217 testing directly in the model, the availability and assumed wide uptake (80%) of over-the-
218 counter self-tests, coupled with the possibility to perform a reflex test promptly to qualify for
219 antiviral administration (≤ 2 days since a positive over-the-counter test), ensured that high-
220 risk individuals can be identified promptly, and yielded the highest average antiviral need at
221 one course for every 4-69 individuals per year (assuming testing rate of 500 tests/100K/day
222 and two 90-day epidemic waves per year; Fig. 4C). For the three LMICs simulated, one
223 antiviral course was distributed for every 73-251 (14-154) persons on average if testing rate
224 was 100 (500) tests/100K/day.

225

226 **Discussion**

227 The current mean LMIC testing rate of 10 tests/100K/day is inadequate to facilitate a test-
228 and-treat program aimed at reducing population-level disease burden. Assuming that antiviral

229 needs can be fully met, increasing test availability to at least 100 tests/100K/day, without
230 imposing any restrictions in access to clinic-provided testing, could avert severe cases by up
231 to 65% in LMICs experiencing an epidemic wave that initialized at $R_t \leq 1.2$. Populations that
232 have an older, high-risk population would avert a larger proportion of severe cases. Crucially,
233 if testing rates are high enough to facilitate a test-and-treat program, the expected reduction in
234 severe cases and deaths due to antivirals improves with the higher vaccination coverage (i.e.
235 between 2.0 and 3.4-fold increase in severe cases averted by antivirals as vaccination
236 coverage increases from 10% to 90%. This emphasizes the importance of linking expanding
237 vaccination coverage in both LMICs and HICs to adequate testing, on top of distributing
238 antivirals.

239

240 If $R_t \geq 1.5$, 100 tests/100K/day is likely insufficient to fully meet testing demand for
241 symptomatic, infected persons who seek clinic-based testing, impeding the identification of
242 high-risk individuals for antiviral treatment. Given that antivirals are unlikely to have an
243 impact of population-level transmission⁵, if the main objective of testing is to maximize the
244 distribution of antivirals to infected high-risk individuals, restricting clinic-based testing to
245 only high-risk symptomatic individuals at testing rates of 100 tests/100K/day could lead to
246 3.3-6.4-fold increase in proportions of severe cases averted relative to the default scenario
247 where no restrictions to clinic-provided testing was imposed. It is also possible to require
248 asymptomatic, high-risk household contacts of test-positive symptomatic individuals to
249 perform self-tests in order to initiate as many high-risk infected individuals to early antiviral
250 treatment as possible. However, setting aside tests for asymptomatic screening when already
251 facing test availability constraints at 100 tests/100K/day would likely diminish the utility of
252 those tests. The proportion of severe cases and deaths averted due to antiviral distribution
253 would also decrease by a relative factor of two to ten-fold under this strategy.

254

255 On the other hand, the availability of over-the-counter self-testing and high testing rates in
256 HICs like the Netherlands is further evidence that high testing volume and the wide
257 accessibility to testing, especially self-testing, are key to the success of antiviral test-and-treat
258 programs. Among the countries simulated, only the Netherlands averted high proportions of
259 severe cases (56-59%) and deaths (67-70%) when $R_t \geq 1.5$ without the need to impose
260 testing restrictions. These results, however, are only possible if clinic-provided testing is
261 maintained at the mean HIC rate of 500 tests/100K/day. If clinical testing volumes were to

262 drop further to 100 tests/100K/day, the expected reduction in severe cases and deaths
263 attributable to antivirals would fall to only 14% and 19% respectively in an epidemic wave
264 initializing at $R_t = 2.0$.

265

266 There have been other modelling efforts estimating the impact of antivirals on epidemic
267 outcomes. First, Leung et al.¹² estimated that distributing antivirals to 50% of all
268 symptomatic infected individuals would only reduce hospitalizations by 10-13% in a
269 population with high vaccination coverage (70-90%).¹² For the Netherlands, we also
270 simulated a population with 80% vaccination coverage and adequate testing availability
271 (including both clinic-based and over-the-counter self-tests) such that at least 50% of all
272 symptomatic individuals were diagnosed. We estimated that 56-59% of severe cases could be
273 averted if only high-risk symptomatic individuals were administered antivirals. When we
274 reconfigured our simulations to now distribute antivirals to 50% of symptomatic infected
275 individuals, the proportion of severe cases averted lower to only 18% which is more in line
276 with Leung et al. A second modelling study found that initiating 20% of infected individuals
277 that were >65 years of age on antivirals daily could avert 32-43% of deaths in an Omicron-
278 like wave ($R_t \geq 2$) for an unvaccinated population in LMICs such as Kenya and Mexico.⁵
279 We had estimated that 31-62% of deaths could be averted at $R_t = 2$ at low (10%) vaccination
280 coverage in LMICs but only if test availability was at the current average HIC mean of 500
281 tests/100K/day and clinic-provided symptomatic testing were restricted to high-risk
282 individuals, in which we would then initiate a daily average of 19-20% of high-risk infected
283 individuals on treatment each day. If there are no restrictions on access to clinic-provided
284 tests, testing rate must be at least 750 tests/100K/day to initiate 20% of infected >65-years on
285 antivirals daily with >95% probability, which is 50% more than the current mean HIC testing
286 rate indicating the previous results for Kenya and Mexico were predicated on very high
287 testing rates.

288

289 There are a few limitations to our work. First, our simulations were based on the estimated
290 effectiveness of nirmatrelvir–ritonavir. We did not consider the clinical benefits of other oral
291 antivirals as nirmatrelvir–ritonavir is the most efficacious antiviral available during the
292 development of this work. Second, we also assumed that vaccine effectiveness against
293 infection is low (29%) based on the average reported protection estimates against Omicron
294 BA.1.¹³⁻¹⁵ Others have shown that with greater vaccine effectiveness against infection (60%),

295 a high vaccination coverage (~70-80%) coupled with antivirals that have an effect in
296 lowering transmissions could synergistically reduce infections in the population.⁵ However,
297 for only ~20% of infections to be averted in an Omicron-like wave, the antiviral must be able
298 to block onward transmission completely after initiating treatment and 30% of symptomatic
299 infected adults must be administered antivirals daily.⁵ Even if an antiviral that is 100%
300 effective in truncating transmissions be developed, testing rate must at least be 764
301 tests/100K/day to initiate 30% of symptomatic infected individuals to treatment daily with
302 >95% probability based on our estimates. Finally, we only simulated scenarios where the
303 only public health interventions against COVID-19 are testing, vaccination and distribution
304 of antivirals. We also did not factor in changes to individual immunity levels due to previous
305 infections or waning. As a simplification, we assumed that the consolidatory effects from
306 other public health measures and varying immunity landscape have been implicitly captured
307 by various initial R_t values when the epidemic wave started.

308

309 As of July 2022, Global Fund and UNICEF are procuring up to 10 million courses of
310 nirmatrelvir–ritonavir for LMICs in 2022/2023.^{16,17} In other words, there would only be one
311 treatment course for every 660 people in LMICs in the coming year (given that the total
312 population size in LMICs stands at ~6.6 billion people¹⁸). In contrast, the United States have
313 procured one course for every 16 persons so far,⁶ well within the range of estimated antiviral
314 need with the expectation of two epidemic waves over the next year (one course per 4-69
315 individuals) in the Netherlands as a HIC archetype. Strikingly, the current 10 million courses
316 of nirmatrelvir–ritonavir set aside for LMICs cannot even fully satisfy the antiviral need
317 averaged across the three LMICs simulated at 100 tests/100K/day for *one* epidemic wave that
318 begins with at $R_t = 0.9$, meeting only 39-47% of potential need. Realistically, having at least
319 two epidemic waves ranging between $R_t = 1.2 - 1.5$ over the next year and aiming to
320 maximally satisfy all antiviral need of LMICs, would mean that the 10 million courses only
321 amount to 4-7% of potential total need. We estimated that LMICs would likely need between
322 26 and 90 million courses in a year if testing rates can be boosted to 100 tests/100K/day.
323 Although Pfizer has agreed to grant sublicenses to manufacture generic versions of
324 nirmatrelvir–ritonavir, it will still take at least one year before they enter the market.
325 Furthermore, middle-income countries are prohibited from procuring generics, thus leaving
326 them to compete with HICs for the remaining 90 million courses Pfizer plans to produce in
327 the second-half of 2022.⁶ Given that unequal access to vaccines and testing have loomed over

328 LMICs over the last two years of the pandemic,^{19,20} the global distribution of oral antiviral
329 therapeutics is likely to only further inequity.

330

331 **Online Methods**

332 *The Propelling Action for Testing And Treating simulation model*

333 Briefly, PATAT creates an age-structured population of individuals within contact networks
334 of multi-generational households, schools, workplaces, regular mass gatherings (e.g. religious
335 gatherings) and random community settings with country-specific demographic data. All
336 simulations begin with 1% of the population infected with SARS-CoV-2 and compute
337 transmissions between individuals across different contact networks each day. Disease
338 progression of infected individuals follows an SEIRD epidemic model, further distinguished
339 by symptom presentation (i.e. asymptomatic, pre-symptomatic, mild or severe disease). For
340 each infected individual, PATAT randomly draws a within-host viral load trajectory, which
341 impacts the sensitivity of Ag-RDTs²¹, based on known distributions for Omicron BA.1²²
342 using previously developed methods.²³ Similar viral load trajectories were drawn for both
343 asymptomatic and symptomatic infected individuals.²⁴

344

345 *Simulation variables*

346 We simulated 90-day epidemic waves caused by an BA.1-like virus in a community of
347 1,000,000 individuals using demographic data collected from three LMICs (i.e. Brazil,
348 Georgia, Zambia) and the Netherlands as a HIC counterpart. For LMICs, we simulated
349 different vaccination coverage (10%, 50% and 90%) while 80% of the population were
350 assumed to be vaccinated in the Netherlands based on estimates on July 2022,²⁵ which is
351 largely comparable to other HICs.²⁶ We randomly assigned vaccination status across the
352 simulated population but assumed that vaccination was age-tiered such that the older
353 individuals were vaccinated first. Based on estimated vaccine effectiveness against BA.1
354 averaged across different vaccines, we assumed that protection rates against infection and
355 severe disease were 29% and 70% respectively.¹³⁻¹⁵

356

357 We did not model varying levels of population immunity due to difficulties in parameterizing
358 the proportion and protection conferred to individuals with infections by single or multiple
359 variants-of-concern in the past. However, we simulated a range of epidemic intensities,
360 measured by the average instantaneous reproduction number (i.e. $R_t = 0.9, 1.2, 1.5, \text{ and } 2.0$)

361 during the first week of each simulation for different vaccination landscapes without test-and-
362 treat programs. As such, the different R_t values can be viewed as the collective outcome of
363 population immunity, intrinsic transmissibility of the transmitted virus as well as effects of
364 existing any public health interventions.

365

366 Besides an age-structured probability of developing severe disease (Extended Data Table 1),
367 we randomly assigned 20% of the population to have a 40% increase in relative risk to
368 developing severe disease due to pre-existing comorbidities (e.g. people living with HIV,
369 obesity, diabetes etc.).^{27,28} As a simplification, we assumed that the prevalence of
370 comorbidities was independent of age.

371

372 *Diagnostic testing*

373 In the model, individuals with symptomatic COVID-19 have a probability of seeking testing
374 at a healthcare facility based on their ability to access a facility (see Supplementary
375 Information). We also estimated symptomatic testing demand from individuals without
376 COVID-19 who sought clinic-provided testing (e.g. individuals who present with similar
377 respiratory symptoms) by assuming a 10% test positivity rate at the start as well as end of an
378 epidemic wave and a 20% test positivity rate at the peak, linearly interpolating the demand
379 for periods between these time points.^{9,10}

380

381 We also simulated scenarios where household contacts of clinic-provided positively-tested
382 individuals were given Ag-RDTs for self-testing for three consecutive days following the
383 positive clinical test of the latter. Adherence (likelihood) to testing by asymptomatic
384 household contacts was assumed to decrease linearly to 50% by the third day. We also
385 simulated an alternative test distribution strategy where we restricted clinic-provided
386 symptomatic testing to high-risk individuals only.

387

388 For LMICs, we modelled three levels of average test availability at healthcare clinics: 10
389 (mean LMIC testing rate as of Q2/2022),⁷ 100 and 500 (mean HIC testing rate as of
390 Q2/2022)⁷ tests/100K/day. For the Netherlands, we performed simulations at clinic-provided
391 testing rates of 100 and 500 tests/100K/day only.

392

393 Based on surveys of pre-COVID-19 pandemic health-seeking behaviour, we assumed that on
394 average 65% of mild symptomatic individuals would seek clinic-provided testing for
395 LMICs²⁹ (and were only tested if there were available test stocks).

396

397 For the Netherlands, however, we assumed that Ag-RDTs are widely available over-the-
398 counter, with no cap on availability. We also assumed that only 10% of mild symptomatic
399 individuals in the Netherlands would seek clinic-provided testing upon symptom onset based
400 on average daily testing rates reported by all Dutch municipal health services in 2021-
401 Q1/2022 (i.e. approximately up to the end of the Omicron BA.1 wave; 7551 tests/100K/day)
402 and Q2/2022 (post Omicron BA.1 wave; 641 tests/100K/day).³⁰ We assumed that 80% of
403 individuals who opted not to seek clinic-provided testing would perform a self-test using an
404 over-the-counter Ag-RDT. We assumed that all high-risk individuals who tested positive
405 would then seek reflexive testing at clinics to be disbursed an antiviral course.

406

407 *Oral antivirals*

408 Regardless of their vaccination status (per WHO guidance³¹), all high-risk individuals who
409 tested positive within five days after symptom onset were eligible for a course of antiviral
410 therapy.^{3,4} We did not impose any caps on antiviral availability as we wanted to estimate the
411 potential number of antiviral courses needed and thus their maximum achievable impact on
412 epidemic outcomes in different scenarios. For all countries, we assumed that antivirals were
413 only administered if high-risk individuals tested positive at clinics (e.g. a self-reported self-
414 test would be insufficient to access antivirals). Although a phase 2/3 trial of nirmatrelvir–
415 ritonavir reported 89% relative risk reduction among unvaccinated high-risk patients infected
416 by the Delta variant-of-concern,³ we assumed that an antiviral course conferred a 46% risk
417 reduction for infected high-risk individuals to severe disease outcomes based on a separate
418 cohort study on the effectiveness of nirmatrelvir–ritonavir among high-risk patients infected
419 by Omicron BA.1 independent of their vaccination status.⁴ We did not factor any risk
420 reduction in transmissions and deaths given the lack and low certainty of evidence of the
421 impact of oral antivirals on protection against infection and mortality respectively.³¹
422 However, in our model, individuals could only die from COVID-19 if they had progressed to
423 severe disease.

424

425 We performed five independent simulations for each combination of parameters described
426 above. All key parameters are tabulated in Extended Data Table 1. Full details of PATAT are

427 described in Han et al.^{9,10} and the Supplementary Information. The PATAT model source
428 code is available at <https://github.com/AMC-LAEB/PATAT-sim>.

429

430 **Data availability**

431 All data relevant to the study are included in the Article, the Supplementary Information and
432 the GitHub repository (<https://github.com/AMC-LAEB/PATAT-sim>). The PATAT model
433 source code can also be found in the GitHub repository
434 (<https://github.com/AMC-LAEB/PATAT-sim>).

435

436 **Funding**

437 This work was supported by the European Research Council [NaviFlu 818353 to A.X.H. and
438 C.A.R.], the National Institutes of Health [5R01AI132362-04 to C.A.R.] and the Dutch
439 Research Council (Nederlandse Organisatie voor Wetenschappelijk Onderzoek) [Vici
440 09150182010027 to C.A.R.]. This work was supported by the Rockefeller Foundation, and
441 the Governments of Germany, Canada, UK, Australia, Norway, Saudi Arabia, Kuwait,
442 Netherlands and Portugal [all authors].

443

444 **Acknowledgements**

445 The authors are pleased to acknowledge that all computational work reported in this paper
446 was performed on the Shared Computing Cluster which is administered by Boston
447 University's Research Computing Services (www.bu.edu/tech/support/research/).

448

449 **Authors' contributions**

450 A.X.H. contributed to the conceptualization, data curation, formal analysis, investigation,
451 methodology, software, validation and visualization of the study. B.E.N. and C.A.R.
452 contributed to the conceptualization, data curation, funding acquisition, investigation,
453 methodology, project administration, resources, validation and supervision of the study. E.H,
454 S.C., and B.R. contributed to the conceptualization, funding acquisition, and validation of the
455 study. A.X.H., B.E.N. and C.A.R. wrote the original draft of the manuscript. All authors were
456 involved in the review and editing of the manuscript. All authors had full access to all data of
457 the study and the final responsibility for the decision to submit for publication.

458

459 **Potential conflicts of interest**

460 The authors declare that they have no competing interests.

461


462 **References**

- 463 1. Singh, M. & de Wit, E. Antiviral agents for the treatment of COVID-19: Progress and
464 challenges. *Cell Rep Med* **3**, 100549 (2022).
- 465 2. Jayk Bernal, A. *et al.* Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized
466 Patients. *New England Journal of Medicine* **386**, 509–520 (2022).
- 467 3. Hammond, J. *et al.* Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with
468 Covid-19. *New England Journal of Medicine* **386**, 1397–1408 (2022).
- 469 4. Najjar-Debbiny, R. *et al.* Effectiveness of Paxlovid in Reducing Severe Coronavirus
470 Disease 2019 and Mortality in High-Risk Patients. *Clinical Infectious Diseases* (2022)
471 doi:10.1093/CID/CIAC443.
- 472 5. Matrajt, L., Brown, E. R., Cohen, M. S., Dimitrov, D. & Janes, H. Could widespread
473 use of antiviral treatment curb the COVID-19 pandemic? A modeling study. *BMC*
474 *Infect Dis* **22**, 1–16 (2022).
- 475 6. Usher, A. D. The global COVID-19 treatment divide. *The Lancet* **399**, 779–782
476 (2022).
- 477 7. FIND. Test tracker - FIND. <https://www.finddx.org/covid-19/test-tracker/> (2022).
- 478 8. Gill, C. J. *et al.* Sustained high prevalence of COVID-19 deaths from a systematic
479 post-mortem study in Lusaka, Zambia: one year later. *medRxiv* 2022.03.08.22272087
480 (2022) doi:10.1101/2022.03.08.22272087.
- 481 9. Han, A. X. *et al.* Strategies for using antigen rapid diagnostic tests to reduce
482 transmission of SARS-CoV-2 in low- and middle-income countries: a mathematical
483 modelling study applied to Zambia. *medRxiv* 2022.06.16.22276516 (2022)
484 doi:10.1101/2022.06.16.22276516.
- 485 10. Han, A. X. *et al.* SARS-CoV-2 diagnostic testing rates determine the sensitivity of
486 genomic surveillance programs. *medRxiv* 2022.05.20.22275319 (2022)
487 doi:10.1101/2022.05.20.22275319.
- 488 11. Wroe, E. B., Seung, K. J., Baker, B. K. & Farmer, P. E. Test and treat: a missing link
489 in the global fight against COVID-19. *Lancet Glob Health* **10**, e181–e182 (2022).

- 490 12. Leung, K., Jit, M., Leung, G. M. & Wu, J. T. The allocation of COVID-19 vaccines
491 and antivirals against emerging SARS-CoV-2 variants of concern in East Asia and
492 Pacific region: A modelling study. *Lancet Reg Health West Pac* **21**, 100389 (2022).
- 493 13. Andrews, N. *et al.* Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529)
494 Variant. *New England Journal of Medicine* **386**, 1532–1546 (2022).
- 495 14. Buchan, S. A. *et al.* Effectiveness of COVID-19 vaccines against Omicron or Delta
496 symptomatic infection and severe outcomes. *medRxiv* 2021.12.30.21268565 (2022)
497 doi:10.1101/2021.12.30.21268565.
- 498 15. Tseng, H. F. *et al.* Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and
499 Delta variants. *Nature Medicine* 2022 28:5 **28**, 1063–1071 (2022).
- 500 16. UNICEF. UNICEF signs supply agreement with Pfizer for oral COVID-19 treatment.
501 [https://www.unicef.org/press-releases/unicef-signs-supply-agreement-pfizer-oral-](https://www.unicef.org/press-releases/unicef-signs-supply-agreement-pfizer-oral-covid-19-treatment)
502 [covid-19-treatment](https://www.unicef.org/press-releases/unicef-signs-supply-agreement-pfizer-oral-covid-19-treatment) (2022).
- 503 17. Global Fund. Global Fund Signs Letter of Intent with Pfizer for Oral COVID-19
504 Treatment. [https://www.theglobalfund.org/en/news/2022/2022-05-20-global-fund-](https://www.theglobalfund.org/en/news/2022/2022-05-20-global-fund-signs-letter-of-intent-with-pfizer-for-oral-covid-19-treatment/)
505 [signs-letter-of-intent-with-pfizer-for-oral-covid-19-treatment/](https://www.theglobalfund.org/en/news/2022/2022-05-20-global-fund-signs-letter-of-intent-with-pfizer-for-oral-covid-19-treatment/) (2022).
- 506 18. United Nations. World Population Prospects - Population Division.
507 <https://population.un.org/wpp/Download/SpecialAggregates/EconomicTrading/>
508 (2022).
- 509 19. Batista, C. *et al.* The silent and dangerous inequity around access to COVID-19
510 testing: A call to action. *EClinicalMedicine* **43**, (2022).
- 511 20. Ye, Y. *et al.* Equitable access to COVID-19 vaccines makes a life-saving difference to
512 all countries. *Nature Human Behaviour* 2022 1–10 (2022) doi:10.1038/s41562-022-
513 01289-8.
- 514 21. Brümmer, L. E. *et al.* Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: A
515 living systematic review and meta-analysis. *PLoS Med* **18**, e1003735- (2021).
- 516 22. Hay, J. A. *et al.* The impact of immune history and variant on SARS-CoV-2 viral
517 kinetics and infection rebound. *medRxiv* 2022.01.13.22269257 (2022)
518 doi:10.1101/2022.01.13.22269257.
- 519 23. Quilty, B. J. *et al.* Quarantine and testing strategies in contact tracing for SARS-CoV-
520 2: a modelling study. *Lancet Public Health* **6**, e175–e183 (2021).
- 521 24. Boyton, R. J. & Altmann, D. M. The immunology of asymptomatic SARS-CoV-2
522 infection: what are the key questions? *Nature Reviews Immunology* 2021 21:12 **21**,
523 762–768 (2021).


- 524 25. National Institute For Public Health and The Environment (RIVM). Figures on the
525 COVID-19 vaccination programme. [https://www.rivm.nl/en/covid-19-](https://www.rivm.nl/en/covid-19-vaccination/figures-vaccination-programme)
526 [vaccination/figures-vaccination-programme](https://www.rivm.nl/en/covid-19-vaccination/figures-vaccination-programme) (2022).
- 527 26. Ritchie, H. *et al.* Coronavirus Pandemic (COVID-19). *Our World in Data* (2020).
- 528 27. Rawshani, A. *et al.* Severe COVID-19 in people with type 1 and type 2 diabetes in
529 Sweden: A nationwide retrospective cohort study. *The Lancet Regional Health -*
530 *Europe* **4**, (2021).
- 531 28. Bertagnolio, S. *et al.* Clinical features of, and risk factors for, severe or fatal COVID-
532 19 among people living with HIV admitted to hospital: analysis of data from the WHO
533 Global Clinical Platform of COVID-19. *Lancet HIV* **9**, e486–e495 (2022).
- 534 29. Dovel, K. *et al.* Frequency of visits to health facilities and HIV services offered to
535 men, Malawi. *Bull World Health Organ* **99**, 618–626 (2021).
- 536 30. National Institute for Public Health and the Environment (RIVM). COVID-19 dataset.
537 <https://data.rivm.nl/covid-19/> (2022).
- 538 31. World Health Organization. Therapeutics and COVID-19: living guideline.
539 <https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.3>
540 (2022).
- 541
- 542

543 **Figures**



544


545 **Fig. 1: Impact of oral antiviral therapy on severe cases in low- and middle-income**
 546 **countries.** No restrictions on access to symptomatic testing at clinics (i.e. all symptomatic
 547 individuals who sought testing at clinics would receive one if in stock) and high-risk
 548 household contacts of test-positive individuals are not tested. All eligible high-risk
 549 individuals (i.e. ≥ 60 years of age or an adult ≥ 18 years with a relevant comorbidity) who
 550 tested positive were given a course of oral antivirals. Line plots (left y-axis) show the
 551 percentage change in severe cases relative to no distribution of antivirals under different
 552 levels of mean test availability (different shades of color) after a 90-day Omicron BA.1-like
 553 epidemic wave in a population of 1,000,000 individuals with (a) 10%, (b) 50%, and (c) 90%
 554 vaccination coverage for different epidemic intensities (measured by the initial instantaneous
 555 reproduction number (R_t); x-axis). Bar plots (right y-axis) show the number of severe cases
 556 in each corresponding scenario. The dotted outline of each bar shows the number of severe
 557 cases of each scenario when no antivirals were distributed.
 558



559

560 **Fig. 2: Impact of oral antiviral therapy on severe cases when restricting symptomatic**
 561 **testing at clinics to high-risk individuals only.** High-risk household contacts of test-positive
 562 individuals are not tested. All eligible high-risk individuals (i.e. ≥ 60 years of age or an adult
 563 ≥ 18 years with a relevant comorbidity) who tested positive were given a course of oral
 564 antivirals. Line plots (left y-axis) show the percentage change in severe cases relative to no
 565 distribution of antivirals under different levels of mean test availability (different shades of
 566 color) after a 90-day Omicron BA.1-like epidemic wave in a population of 1,000,000
 567 individuals with (a) 10%, (b) 50%, and (c) 90% vaccination coverage for different epidemic
 568 intensities (measured by the initial instantaneous reproduction number (R_t); x-axis). Bar plots
 569 (right y-axis) show the number of severe cases in each corresponding scenario. The dotted
 570 outline of each bar shows the number of severe cases of each scenario when no antivirals
 571 were distributed.


572




573

574 **Fig. 3: Impact of oral antiviral therapy in a high-income country (Netherlands).** No
575 restrictions on access to symptomatic testing at clinics (i.e. all symptomatic individuals who
576 sought testing at clinics would receive one if in stock) and high-risk household contacts of
577 test-positive individuals are not tested. Over-the-counter antigen rapid diagnostic tests (Ag-
578 RDTs) are assumed to be widely available. As such, we assumed that only 10% of
579 symptomatic individuals would seek clinical testing directly while 80% of those who opted
580 not to seek clinic-provided testing would perform self-testing using over-the-counter Ag-
581 RDTs. All high-risk individuals who tested positive through self-testing would seek reflexive
582 testing at clinics on the same day. All eligible high-risk individuals (i.e. ≥ 60 years of age or
583 an adult ≥ 18 years with a relevant comorbidity) who tested positive at clinics, either directly
584 or through reflexive testing, were given a course of oral antivirals. Line plots (left y-axis)
585 show the percentage change in (a) total infections, (b) severe cases and (c) deaths relative to
586 no distribution of antivirals under different clinical testing rates (different shades of color)
587 after a 90-day Omicron BA.1-like epidemic wave in a population of 1,000,000 individuals
588 80% vaccination coverage for different epidemic intensities (measured by the initial
589 instantaneous reproduction number (R_t); x-axis). Bar plots (right y-axis) show the number of
590 severe cases in each corresponding scenario. The dotted outline of each bar shows the
591 number of severe cases of each scenario when no antivirals were distributed.
592


a) Vaccination coverage = 10%



b) Vaccination coverage = 50%



c) Vaccination coverage = 90% (LMICs); 80% (Netherlands)



593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609

Fig. 4: Estimated need of oral antivirals. Line plots show the ratio of estimated oral antiviral courses needed to number of people per year (expressed as 1 oral antiviral course per n number of individuals; assuming two epidemic waves a year) in various countries (color) under different simulated scenarios (i.e. testing rate at 100 or 500 tests/100,000 people/day (shading and linestyle) and distribution modality (left plot panel: test all symptomatic individuals who sought testing at clinics; middle plot panel: test all symptomatic individuals who sought testing as well as distributing clinic-provided self-tests to high-risk asymptomatic household contacts of test-positive individuals; right plot panel: test only high-risk symptomatic individuals who sought testing at clinics). All test-positive eligible high-risk individuals from clinic-provided testing would receive a course of oral antivirals. For the Netherlands, over-the-counter antigen rapid diagnostic tests (Ag-RDTs) are assumed to be widely available that most high-risk individuals would perform a self-test first and only seek reflexive testing at clinics if their over-the-counter tests were positive. **(a)** 10%, **(b)** 50% and **(c)** 90% (Low and middle-income countries; LMICs); 80% (Netherlands) vaccination coverage assumed for the simulated population.

610 **Tables**

611 **Table 1. Fold increase in proportion of severe cases averted due to distribution of oral**
 612 **antivirals when increasing vaccination coverage from 10% to 90%. No restrictions on**
 613 **access to symptomatic testing at clinics (i.e. all symptomatic individuals who sought testing**
 614 **at clinics would receive one if in stock) and high-risk household contacts of test-positive**
 615 **individuals are not tested.**
 616

Country	Testing rate (tests/100,000 people/day)	R_t	Fold increase
Brazil	100	0.9	2.30
		1.2	2.13
		1.5	3.00
		2.0	No further increase
	500	0.9	1.17
		1.2	1.28
		1.5	3.33
		2.0	1.53
Georgia	100	0.9	1.31
		1.2	2.21
		1.5	3.40
		2.0	No further increase
	500	0.9	1.00
		1.2	1.02
		1.5	2.72
		2.0	1.63
Zambia	100	0.9	1.19
		1.2	1.36
		1.5	1.96
		2.0	No further increase
	500	0.9	1.30
		1.2	1.43
		1.5	1.81
		2.0	1.23

617

618